RWRMTN

RWRMTN predicts disease-associated microRNAs (miRNAs) by applying a random walk algorithm to miRNA-target gene networks to prioritize miRNAs linked to disease via mutual regulation with their target genes.


Key Features:

  • Random Walk Framework: Employs a random walk algorithm on miRNA-target gene networks to capture network topology and mutual regulatory relationships between miRNAs and target genes.
  • Enhanced Prediction Performance: Demonstrates improved predictive capability compared to existing network- and machine learning–based methods by exploiting mutual regulation within miRNA-target networks.
  • Versatility Across Networks: Operates on any miRNA-target gene network, enabling application to diverse datasets.
  • Evidence-Based Ranking: Produces ranked candidate miRNAs with support from existing literature evidence.
  • Automation and Workflow Integration: Provides automation features for incorporation into external computational workflows.

Scientific Applications:

  • miRNA–disease association prediction: Prioritizes miRNAs potentially associated with diseases in which miRNA dysregulation is implicated.
  • Biomarker and therapeutic target identification: Supports identification of candidate miRNA biomarkers and therapeutic targets linked to disease processes.
  • Oncology applications: Applied to predict miRNAs associated with breast cancer and lung cancer.

Methodology:

Constructing a network model of miRNA–target gene interactions and applying a random walk algorithm that exploits mutual regulatory relationships to predict disease associations and rank candidate miRNAs.

Topics

Details

Programming Languages:
Java
Added:
1/18/2021
Last Updated:
2/10/2021

Operations

Publications

Le D, Tran TTH. RWRMTN: a tool for predicting disease-associated microRNAs based on a microRNA-target gene network. BMC Bioinformatics. 2020;21(1). doi:10.1186/s12859-020-03578-3. PMID:32539680. PMCID:PMC7296691.

PMID: 32539680
PMCID: PMC7296691
Funding: - National Foundation for Science and Technology Development: 102.01-2017.14

Links